SEC Filing · 6-K
Evaxion A/S
SEC Filing
Press release in this filing
New phase 2 data highlight the strength of the immune response induced by personalized cancer vaccine EVX-01 →Company context
Evaxion A/S is a pioneering clinical-stage TechBio company based upon the Artificial Intelligence (AI) platform: AI-Immunology™. The AI-Immunology™ platform consists of five proprietary and scalable AI prediction models harnessing the power of data, machine learning and artificial intelligence to decode the human immune system. This enables the development of novel vaccines for the treatment of cancer as well as bacterial and viral infections.
Current securities
As-filed source
As filedOpen full document ↗